← Leaderboards
Vassiliki A Boussiotis
Beth Israel Deaconess Medical Center
$19,288,605
Attributed
$25,285,610
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,285,610 · 16
By mechanism
R01$22,202,916 · 10
R21$1,435,312 · 3
R35$846,982 · 1
R56$800,400 · 2
Top collaborators
- Alain Charest11 shared
- Corey S Cutler5 shared
- Roel Gw Verhaak3 shared
- Ioannis Vlachos3 shared
- Sizun Jiang1 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Corey S Cutler$6,266,747
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMolecularT-LymphocyteTumorMediatingResponseImmunePropertyAffectProgramsPathway InteractionsCd8b1 GeneSignal TransductionMalignant NeoplasmsGenerationsRegulatory T-LymphocytePhosphorylationGenesImmunityCd8-Positive T-LymphocytesNovel StrategiesClinical TrialsIn VivoImmunologics
Grant awards (56)
Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy$846,982
R35 · FY2025 · CA · contact PI
Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy$709,419
R01 · FY2025 · CA · contact PI
Dissecting Orchestrated Immune Responses to Glioblastoma within the Native Tissue Microenvironment to Improve Treatment Outcomes$687,279
R01 · FY2025 · NS
Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments.$648,380
R01 · FY2025 · CA
Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy$675,994
R01 · FY2024 · CA · contact PI
The effects of PD-1 on tumor-mediated âemergencyâ myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity$623,127
R01 · FY2024 · CA · contact PI
Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments.$618,825
R01 · FY2024 · CA
Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy$722,621
R01 · FY2023 · CA · contact PI
Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments.$672,634
R01 · FY2023 · CA
The effects of PD-1 on tumor-mediated âemergencyâ myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity$591,222
R01 · FY2023 · CA · contact PI
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma$635,966
R01 · FY2022 · CA
The effects of PD-1 on tumor-mediated âemergencyâ myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity$591,222
R01 · FY2022 · CA · contact PI
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma$44,396
R01 · FY2022 · CA
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma$648,944
R01 · FY2021 · CA
The effects of PD-1 on tumor-mediated âemergencyâ myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity$631,075
R01 · FY2021 · CA · contact PI
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect$571,003
R01 · FY2021 · CA · contact PI
Advancing Treatment Outcomes in Malignant Glioma by Integrating Immunotherapy and Standard of Care using Genetically Engineered Mice that Recapitulate Molecular Feature of Human Glioma$45,302
R01 · FY2021 · CA
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma$648,944
R01 · FY2020 · CA
The effects of PD-1 on tumor-mediated âemergencyâ myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity$642,962
R01 · FY2020 · CA · contact PI
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect$571,003
R01 · FY2020 · CA · contact PI
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma$629,475
R01 · FY2019 · CA
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect$553,873
R01 · FY2019 · CA · contact PI
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma$667,694
R01 · FY2018 · CA
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect$517,798
R01 · FY2018 · CA · contact PI
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT$894,037
R01 · FY2017 · CA · contact PI
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect$536,535
R01 · FY2017 · CA · contact PI
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT$536,875
R01 · FY2016 · CA · contact PI
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT$355,157
R01 · FY2016 · CA · contact PI
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT$536,875
R01 · FY2015 · CA · contact PI
Effects of PGE2 on Reconstitution of Hematopoiesis and Immunity after UCBT$374,707
R01 · FY2015 · CA · contact PI
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT$520,769
R01 · FY2014 · CA · contact PI
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT$573,875
R01 · FY2013 · CA · contact PI
The role of RIAM in T cell immunity and tolerance$408,900
R56 · FY2013 · AI · contact PI
Prevention of acute GvHD by inhibition of cdk2$253,224
R21 · FY2012 · HL · contact PI
The role of Rap1 and its novel associated molecules in T cell responses$391,500
R56 · FY2011 · AI · contact PI
Prevention of acute GvHD by inhibition of cdk2$228,432
R21 · FY2011 · HL · contact PI
Reconstitution of T cell immunity after UCB transplantation: The role of Treg$390,741
R21 · FY2009 · CA · contact PI
Expression and Function of Tob in T Lymphocytes$318,352
R01 · FY2009 · CA · contact PI
The Role of Rap1 in T-Cell Responses$316,256
R01 · FY2009 · AI · contact PI
Reconstitution of T cell immunity after UCB transplantation: The role of Treg$391,915
R21 · FY2008 · CA · contact PI
Expression and Function of Tob in T Lymphocytes$318,352
R01 · FY2008 · CA · contact PI
The Role of Rap1 in T-Cell Responses$195,043
R01 · FY2008 · AI · contact PI
The Role of Rap1 in T-Cell Responses$117,801
R01 · FY2008 · AI · contact PI
The Role of Rap1 in T-Cell Responses$324,752
R01 · FY2007 · AI · contact PI
Expression and Function of Tob in T Lymphocytes$316,479
R01 · FY2007 · CA · contact PI
The Role of Rap1 in T-Cell Responses$334,451
R01 · FY2006 · AI · contact PI
Expression and Function of Tob in T Lymphocytes$325,931
R01 · FY2006 · CA · contact PI
Expression and Function of Tob in T Lymphocytes$333,775
R01 · FY2005 · CA
The Role of Rap1 in T-Cell Responses$291,125
R01 · FY2005 · AI
The role of p27kip1 in T-cell Responses$296,682
R01 · FY2003 · AI
The Role of Rap1 in T-Cell Responses$171,000
R21 · FY2003 · AI
The role of p27kip1 in T-cell Responses$267,091
R01 · FY2002 · AI
RAP1 AND ASSOCIATED MOLECULES AND T CELL ANERGY$117,600
R01 · FY2002 · AI
The role of p27kip1 in T-cell responses$287,511
R01 · FY2001 · AI
RAP1 AND ASSOCIATED MOLECULES AND T CELL ANERGY$189,668
R01 · FY2001 · AI
RAP1 AND ASSOCIATED MOLECULES AND T CELL ANERGY$174,059
R01 · FY2000 · AI